Danilo M. dos Santos, Hasika Suresh, Samantha J. Kruzshak, Jihyun Kim, Peggy Cebe, James D. Baleja, Emmanuel S. Tzanakakis, Sameer Sonkusale
{"title":"Engineering Eutectogel Microneedle Patch as Effective Transdermal Delivery System of Hydrophobic Drugs","authors":"Danilo M. dos Santos, Hasika Suresh, Samantha J. Kruzshak, Jihyun Kim, Peggy Cebe, James D. Baleja, Emmanuel S. Tzanakakis, Sameer Sonkusale","doi":"10.1002/adtp.202400521","DOIUrl":null,"url":null,"abstract":"<p>Conventional drug delivery methods often face challenges in terms of patient adherence and drug administration. Microneedles (MNs) patches have emerged as a promising alternative, offering a minimally invasive transdermal route for medications. However, their drug-loading capacity remains limited, particularly for hydrophobic active pharmaceutical ingredients (APIs). Herein, microneedles are designed based on eutectic solvent gels (eutectogels) as transdermal carriers for hydrophobic APIs. A natural deep eutectic solvent (NADES) is combined to enhance the solubility of the hydrophobic APIs within the GelMA/PEGDA matrix for mechanical strength and sustained release from the resulting eutectogels microneedles (EU-MNs). Using docetaxel, 5-fluorouracil, and curcumin as hydrophobic APIs models, the superior drug-loading capacity of the EU-MNs is demonstrated. In vitro experiments revealed that the EU-MNs provided a sustained release of distinct hydrophobic APIs over 4 days. Additionally, by properly adjusting the concentration and type of APIs, these microneedle patches do not exhibit cytotoxic effects on fibroblasts cell line (NIH/3T3), underscoring their potential for safe and effective transdermal drug delivery. These findings highlight the potential of EU-MNs as versatile, eco-friendly transdermal vehicles for large amounts of hydrophobic APIs, leading to more effective treatments for these drugs.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adtp.202400521","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Conventional drug delivery methods often face challenges in terms of patient adherence and drug administration. Microneedles (MNs) patches have emerged as a promising alternative, offering a minimally invasive transdermal route for medications. However, their drug-loading capacity remains limited, particularly for hydrophobic active pharmaceutical ingredients (APIs). Herein, microneedles are designed based on eutectic solvent gels (eutectogels) as transdermal carriers for hydrophobic APIs. A natural deep eutectic solvent (NADES) is combined to enhance the solubility of the hydrophobic APIs within the GelMA/PEGDA matrix for mechanical strength and sustained release from the resulting eutectogels microneedles (EU-MNs). Using docetaxel, 5-fluorouracil, and curcumin as hydrophobic APIs models, the superior drug-loading capacity of the EU-MNs is demonstrated. In vitro experiments revealed that the EU-MNs provided a sustained release of distinct hydrophobic APIs over 4 days. Additionally, by properly adjusting the concentration and type of APIs, these microneedle patches do not exhibit cytotoxic effects on fibroblasts cell line (NIH/3T3), underscoring their potential for safe and effective transdermal drug delivery. These findings highlight the potential of EU-MNs as versatile, eco-friendly transdermal vehicles for large amounts of hydrophobic APIs, leading to more effective treatments for these drugs.